hypoglycemia and glp-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Favorable Effects of GLP-1 Receptor

According to Truveta Research presented at ISPOR 2025, side effects were the leading reason patients stopped taking GLP-1 medications, accounting for 28.2% of all discontinuations

Moreover, patients may be prescribed a drug but may not be taking it as prescribed

GLP-1s are known to reduce both fat and muscle mass and discontinuation typically results in weight regainprimarily as fat massresulting in a less healthy body composition compared to treatment initiation

Third: choosing GLP-3(Reta) when the glucagon receptor pathway is a specific study target, or when the research design is exploring the absolute ceiling of receptor-mediated metabolic effects

obtained from Boehringer Ingelheim, Ingelheim am Rhein, Germany)